Cargando…

Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway

Pulmonary arterial hypertension (PAH) is a severe disease with a resultant increase of the mean pulmonary arterial pressure, right ventricular hypertrophy and eventual death. Research in recent years has produced various therapeutic options for its clinical management but the high mortality even und...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tettey, Abraham, Jiang, Yujie, Li, Xiaohui, Li, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633825/ https://www.ncbi.nlm.nih.gov/pubmed/34867394 http://dx.doi.org/10.3389/fphar.2021.767002

Ejemplares similares

Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways
por: Mandras, Stacy, et al.
Publicado: (2021)

Nitric oxide and pulmonary arterial hypertension
por: Chester, Adrian H., et al.
Publicado: (2017)

An electrochemical nitric oxide generator for in-home inhalation therapy in pulmonary artery hypertension
por: Liu, Yiwei, et al.
Publicado: (2022)

New hope for Nutlin-3a therapy for pulmonary arterial hypertension
por: Fukumoto, Jutaro, et al.
Publicado: (2013)

Targeting L-arginine-nitric oxide-cGMP pathway in pulmonary arterial hypertension
por: Tang, Haiyang, et al.
Publicado: (2017)

Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension
por: Chen, Yong-Jie, et al.
Publicado: (2021)

Nitric oxide and pulmonary hypertension
por: Sim, Ji-Yeon
Publicado: (2010)

Don’t stop at first glance: pulmonary artery angiosarcoma mimicking chronic thromboembolic pulmonary hypertension
por: Correale, Michele, et al.
Publicado: (2018)

Commentary: The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension
por: Bhavanam, Naga P., et al.
Publicado: (2015)

Diabetes Attenuates the Contribution of Endogenous Nitric Oxide but Not Nitroxyl to Endothelium Dependent Relaxation of Rat Carotid Arteries
por: Li, Jasmin Chendi, et al.
Publicado: (2021)

Emerging Pathogenetic Mechanisms of Pulmonary Arterial Hypertension: Nitric Oxide and More
por: Kim, Young Dae
Publicado: (2011)

Acute nitric oxide synthase inhibition and endothelin-1-dependent arterial pressure elevation
por: Rapoport, Robert M.
Publicado: (2014)

Gallic Acid Attenuates Angiotensin II-Induced Hypertension and Vascular Dysfunction by Inhibiting the Degradation of Endothelial Nitric Oxide Synthase
por: Yan, Xiao, et al.
Publicado: (2020)

Intervening with the Nitric Oxide Pathway to Alleviate Pulmonary Hypertension in Pulmonary Vein Stenosis
por: van Duin, Richard W. B., et al.
Publicado: (2019)

Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy
por: Tonelli, Adriano R., et al.
Publicado: (2013)

Efficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis
por: Zhang, Ruihua, et al.
Publicado: (2022)

Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension
por: Xue, Zhifeng, et al.
Publicado: (2021)

Leflunomide-induced pulmonary arterial hypertension in a young man with nephrotic syndrome: A case report
por: Luo, Xiaoqin, et al.
Publicado: (2022)

Novel Pyrazolo[3,4-b] Pyridine Derivative (HLQ2g) Attenuates Hypoxic Pulmonary Hypertension via Restoring cGKI Expression and BMP Signaling Pathway
por: Li, Lijun, et al.
Publicado: (2021)

The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Luteolin Ameliorates Experimental Pulmonary Arterial Hypertension via Suppressing Hippo-YAP/PI3K/AKT Signaling Pathway
por: Zuo, Wanyun, et al.
Publicado: (2021)

Centella asiatica (L.) Urb. Prevents Hypertension and Protects the Heart in Chronic Nitric Oxide Deficiency Rat Model
por: Bunaim, Mohd Khairulanwar, et al.
Publicado: (2021)

Multifunctional role of natural products for the treatment of Parkinson’s disease: At a glance
por: Rahman, Md. Mominur, et al.
Publicado: (2022)

Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models
por: Li, Huayang, et al.
Publicado: (2021)

Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension
por: Alencar, Allan K. N., et al.
Publicado: (2017)

Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
por: Tong, Yi, et al.
Publicado: (2018)

Xiongshao Zhitong Recipe Attenuates Nitroglycerin-Induced Migraine-Like Behaviors via the Inhibition of Inflammation Mediated by Nitric Oxide Synthase
por: Yang, Song, et al.
Publicado: (2022)

Combination Therapy With Rapamycin and Low Dose Imatinib in Pulmonary Hypertension
por: Shi, Yinan, et al.
Publicado: (2021)

Human Mesenchymal Stem Cell Therapy Reverses Su5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Mice
por: Alencar, Allan K. N., et al.
Publicado: (2018)

Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension
por: Blanco, Isabel, et al.
Publicado: (2023)

Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
por: Dong, Wenxing, et al.
Publicado: (2023)

Apelin Does Not Impair Coronary Artery Relaxation Mediated by Nitric Oxide-Induced Activation of BK(Ca) Channels
por: Mughal, Amreen, et al.
Publicado: (2021)

Text Mining-Based Drug Discovery for Connective Tissue Disease–Associated Pulmonary Arterial Hypertension
por: Tan, Jiang-Shan, et al.
Publicado: (2022)

Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD
por: Alqarni, Abdullah A., et al.
Publicado: (2023)

Supplementation with Tex261 provides a possible preventive treatment for hypoxic pulmonary artery hypertension
por: Chen, Shaokun, et al.
Publicado: (2022)

Inhibition of nitric oxide synthase unmasks vigorous vasoconstriction in established pulmonary arterial hypertension
por: Tanaka, Mariko, et al.
Publicado: (2017)

Exhaled nitric oxide is not a biomarker for idiopathic pulmonary arterial hypertension or for treatment efficacy
por: Malekmohammad, Majid, et al.
Publicado: (2019)

Role of heparanase in pulmonary hypertension
por: Wang, Lin-Jun, et al.
Publicado: (2023)

Magnolol Attenuates Right Ventricular Hypertrophy and Fibrosis in Hypoxia-Induced Pulmonary Arterial Hypertensive Rats Through Inhibition of the JAK2/STAT3 Signaling Pathway
por: Fu, Minyi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hkn19pt8a6s51s19l6ncerh1f7